Search research articles
Contact Us
Filters
Showing results (41-50 of 79) with videos related to
Page
of 8
Sort By:
Clinical Therapeutics
|
November 2, 2024
Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β-Thalassemia in England
Chuka Udeze, Nelly F Ly, Fiona C Ingleby, et al.
Clinical Therapeutics
|
November 7, 2024
Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England
Chuka Udeze, Nelly F Ly, Fiona C Ingleby, et al.
American Journal of Hematology
|
September 29, 2011
Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry
Annette Gilmore, Gavin Cho, Jo Howard, et al.
Transfusion
|
April 27, 2018
Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline
Veerle Compernolle, Stella T Chou, Susano Tanael, et al.
Clinical and Translational Science
|
January 1, 2019
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study
Robert J Charnigo, David Beidler, Denis Rybin, et al.
Platelets
|
August 21, 2014
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease
Joseph A Jakubowski, Chunmei Zhou, Kenneth J Winters, et al.
Thrombosis Research
|
December 26, 2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Joseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, et al.
British Journal of Clinical Pharmacology
|
November 23, 2012
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity
Joseph A Jakubowski, Chunmei Zhou, David S Small, et al.
The Lancet. Haematology
|
April 10, 2021
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial
Jo Howard, Kenneth I Ataga, Robert C Brown, et al.
Blood Advances
|
January 11, 2024
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
Deva Sharma, Ilknur Kozanoğlu, Kenneth I Ataga, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 79) with videos related to
Sort By:
Page
of 8
Clinical Therapeutics
|
November 2, 2024
Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent β-Thalassemia in England
Chuka Udeze, Nelly F Ly, Fiona C Ingleby, et al.
Clinical Therapeutics
|
November 7, 2024
Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England
Chuka Udeze, Nelly F Ly, Fiona C Ingleby, et al.
American Journal of Hematology
|
September 29, 2011
Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry
Annette Gilmore, Gavin Cho, Jo Howard, et al.
Transfusion
|
April 27, 2018
Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline
Veerle Compernolle, Stella T Chou, Susano Tanael, et al.
Clinical and Translational Science
|
January 1, 2019
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study
Robert J Charnigo, David Beidler, Denis Rybin, et al.
Platelets
|
August 21, 2014
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease
Joseph A Jakubowski, Chunmei Zhou, Kenneth J Winters, et al.
Thrombosis Research
|
December 26, 2013
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Joseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, et al.
British Journal of Clinical Pharmacology
|
November 23, 2012
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity
Joseph A Jakubowski, Chunmei Zhou, David S Small, et al.
The Lancet. Haematology
|
April 10, 2021
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial
Jo Howard, Kenneth I Ataga, Robert C Brown, et al.
Blood Advances
|
January 11, 2024
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel
Deva Sharma, Ilknur Kozanoğlu, Kenneth I Ataga, et al.
Page
of 8